Complementary Alternative Cardiovascular Medicine

200 Alternative Cardiovascular Medicine
31. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R,
Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension
1997;29:999–1006.
32. Heinecke JW. Sources of vascular oxidative stress. In: Keaney JF, Jr., ed. Oxidative
stress and vascular disease. Kluwer Academic Publishers, Boston, 2000, pp. 9–25.
33. Esterbauer H, Striegl H, Puhl H, Rotheneder M. Continuous monitoring of in vitro
oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67–75.
34. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, Thorpe SR. Formation
of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation.
J Biol Chem 1993;268:12,341–12,347.
35. Swain J, Gutteridge JM. Prooxidant iron and copper, with ferroxidase and xanthine
oxidase activities in human atherosclerotic material. FEBS Lett 1995;368:513–515.
36. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation
and hydroxyl-radical generation by the contents of human atherosclerotic lesions.
Biochem J 1992;286:901–905.
37. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H. Role of iron in NFkappa
B activation and cytokine gene expression by rat hepatic macrophages. Am
J Physiol 1997;272:G1355–G1364.
38. Olbrych MT, Khan BV, Alexander RW, Medford RM. Metal dependent and independent
regulation of redox-sensitive VCAM-1 gene expression in human vascular
endothelial cells [abstract]. Circulation 1995;92:I–229.
39. Cooper CE. Nitric oxide and iron proteins. Biochim Biophys Acta 1999;1411:290–309.
40. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery
responses to physiological stimuli are improved by deferoxamine but not by Larginine
in non-insulin-dependent diabetic patients with angiographically normal
coronary arteries and no other risk factors. Circulation 1998;97:736–743.
41. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial
function in patients with coronary artery disease. Circulation 2001;103:2799–2804.
42. Galey J-P. Potential use of iron chelators against oxidative damage. In: Sies H, ed.
Antioxidants in Disease: Mechanisms and Therapy. Academic, San Diego, 2001,
pp. 167–203.
43. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide mediated modification of low
density lipoprotein by arterial smooth muscle cells in culture. J Clin Invest
1986;77:757–761.
44. Green DJ, O’Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor
RR. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related
endothelial vasodilator function. Clin Exp Pharmacol Physiol 1999;26:853–856.
45. Astin JA. Why patients use alternative medicine: results of a national study. JAMA
1998;279:1548–1553.
46. ACC/AHA guideline for the Management of Stable Angina. J Am Coll Cardiol
1999;33:2092–2197.
47. Rosema T. The protocol for safe and effective administration of EDTA and other
chelation agents for vascular disease, degenerative disease and metal toxicity. J Adv
Med 1997;10:5–100.